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G protein-coupled receptors are a major class of
membrane receptors that mediate physiological
and pathophysiological cellular signaling. Many as-
pects of receptor activation and signaling can be
investigated using genetically encoded luminescent
fusion proteins. However, the use of these biosen-
sors in live cell systems requires the exogenous
expression of the tagged protein of interest. Tomain-
tain the normal cellular context here we use CRISPR/
Cas9-mediated homology-directed repair to insert
luminescent tags into the endogenous genome. Us-
ingNanoLuc and bioluminescence resonance energy
transfer we demonstrate fluorescent ligand binding
at genome-edited chemokine receptors. We also
demonstrate that split-NanoLuc complementation
can be used to investigate conformational changes
and internalization of CXCR4 and that recruitment
of b-arrestin2 to CXCR4 can be monitored when
both proteins are natively expressed. These results
show that genetically encoded luminescent biosen-
sors can be used to investigate numerous aspects
of receptor function at native expression levels.
INTRODUCTION
G protein-coupled receptors (GPCRs) are a major class of mem-
brane receptors that control numerous physiological responses
via ligand-mediated signal transduction. The response elicited
by a given GPCR is dependent on the cellular context, i.e., the
cellular proteome and a cascade of factors including receptor
compartmentalization (Ellisdon and Halls, 2016; Tsvetanova
et al., 2015), association with interacting proteins (BockaertCell Chemical Biology 27, 1–12
This is an open access article undet al., 2004), binding of a specific ligand and subsequent confor-
mational rearrangement resulting in activation (Wang et al.,
2018), coupling to specific intercellular effectors (e.g., G pro-
teins) (Wang et al., 2018; Rankovic et al., 2016), or scaffolding
proteins (e.g., GPCR kinases and arrestins) (Walther and Fergu-
son, 2015), as well as internalization, trafficking, and recycling of
the receptor (Magalhaes et al., 2012). Many of these processes
can be studied using genetically encoded luminescent and/or
fluorescent fusion proteins that allow for investigation of receptor
or protein function by sensitive microscopic or biophysical tech-
niques such as resonance energy transfer. Indeed, luciferase-
based assays have been developed to investigate GPCR-ligand
binding (Stoddart et al., 2015), G protein activation, and protein-
protein interactions (Lohse et al., 2012), as well as receptor inter-
nalization and trafficking (Lan et al., 2012; Tiulpakov et al., 2016)
by monitoring changes in bioluminescence resonance energy
transfer (BRET) or luciferase complementation. However, the
use of these biosensors in cellular systems is typically accom-
plished by exogenous expression of the tagged protein(s) of
interest that can perturb the normal cellular context and stoichi-
ometry of the cellular interactome, particularly where the level of
exogenous expression is high.
To overcome the need for exogenous expression of a lucif-
erase-tagged protein of interest in BRET assays, we and others
have used CRISPR/Cas9 genome engineering to insert the
19-kDa nanoluciferase (NanoLuc, NLuc) into endogenous
mammalian loci via homology-directed recombination (White
et al., 2017, 2019; Oh-Hashi et al., 2016). This results in NLuc
fusion proteins being expressed under endogenous promotion
and has been used to investigate ligand binding to adenosine
A2B receptors (White et al., 2019), as well as CXCR4 receptor
trafficking and b-arrestin2 recruitment to GPCRs (White et al.,
2017) by monitoring changes in resonance energy transfer be-
tween the NLuc luminescent donor and a fluorescent acceptor.
In addition, reports have also demonstrated the use of CRISPR/
Cas9 genome editing to insert small self-complementing frag-
ments of NLuc into the endogenous genome (Oh-Hashi et al.,, April 16, 2020 ª 2020 The Author(s). Published by Elsevier Ltd. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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fication of protein expression by changes in luminescence
following luciferase complementation (Oh-Hashi et al., 2017;
Schwinn et al., 2018) as well as post-translational modifications
of endogenous proteins to be investigated by NanoBRET (with
addition of an exogenous fluorescent probe) (Schwinn et al.,
2018). The split NLuc system (NanoBiT) comprises a small
11-amino acid peptide engineered to interact with an 18-kDa
polypeptide of NLuc (LgBiT) with either high (700 pM) or
low (190 mM) affinity (Dixon et al., 2016). These two high-
and low-affinity systems can therefore be configured to inves-
tigate either transient or stable protein interactions. Indeed,
using exogenously expressed proteins, multiple studies now
report monitoring GPCR-protein interactions and receptor
internalization, as well as changes in protein expression, with
the NanoBiT system (Reyes-Alcaraz et al., 2018; Dixon et al.,
2016; Laschet et al., 2019; Storme et al., 2018).
Despite these advances in the NanoBRET and nanoluciferase
complementation techniques, an outstanding limitation is that
the investigation of protein-protein interactions still requires
exogenous expression of protein tagged with a fluorescent
acceptor. Tagging endogenous proteins with a fluorescent pro-
tein is readily achievable (Kamiyama et al., 2016), while the sensi-
tivity of nanoluciferase complementation should be sufficient
to detect interactions between two genome-edited proteins.
However, to our knowledge no studies have reported using
NanoBRET or NanoBiT complementation to investigate interac-
tions between two proteins expressed under endogenous
promotion. Furthermore, these genome-edited nanoluciferase
techniques have, so far, only been established on a few recep-
tors and assay configurations.
Using CRISPR/Cas9, here we aimed to further apply and
develop genome-edited NLuc/NanoBiT-based assays that can
be used to investigate GPCR function with proteins expressed
under endogenous promotion. We demonstrate that multiple as-
pects of chemokine receptor signaling can be investigated using
these genome-edited NanoBRET/NanoBiT techniques including
quantification of endogenous receptor expression and ligand
binding aswell as receptor conformational changes and internal-
ization. We also established that ligand-mediated recruitment of
b-arrestin2 to CXCR4 can be observed when both proteins are
endogenously expressed. Finally, these approaches allowed
for the comparison of responses mediated by exogenous and
genome-edited proteins and therefore discussion of the associ-
ated caveats.
RESULTS
Genome Engineering
Here we used CRISPR/Cas9-mediated homology-directed
repair to successfully generate genome-edited HEK293 cells
expressing CXCR4 tagged on the N terminus with NLuc
or the modified 11-amino acid high-affinity NLuc fragment
(Kd  700 pM, HiBiT [Dixon et al., 2016]) yielding NLuc/CXCR4
and HiBiT/CXCR4, respectively. We also generated HEK293
cells expressing genome-edited b-arrestin2 (also known as ar-
restin-3) tagged on the C terminus with the modified low-affinity
11-amino acid NLuc fragment (Kd  190 mM, SmBiT [Dixon et al.,
2016]; b-arrestin2/SmBiT) as well as HeLa cells expressing2 Cell Chemical Biology 27, 1–12, April 16, 2020genome-edited NLuc/CXCR4 or ACKR3 tagged on the N termi-
nus with NLuc (NLuc/ACKR3). In agreement with a lack of
detectable ACKR3mRNA in HEK293 cells (Thul et al., 2017) (Fig-
ure S1), no clones expressing NLuc/ACKR3 could be generated.
All cells lines tested were heterozygous for the insert (Figures
S1C–S1F) as is typical of non-diploid cell lines such as triploidic
to tetraploidic HEK293 cells (Stepanenko and Dmitrenko, 2015),
which results in homozygous knockin being a rare occurrence.
Analysis of CXCR4 and ARRB2 (genes encoding CXCR4 and
b-arrestin2) mRNA levels following CRISPR/Cas9-mediated
tagging showed significant variation in CXCR4 expression be-
tween HEK293 or HeLa cell lines (Figures 1A and 1B; p <
0.01); however, no significant differences in ARRB2 expression
in HEK293 cells were observed (Figure 1C). Bioluminescence im-
aging of cells expressing genome-edited NLuc/CXCR4 (Figures
1D and 1E) showed localization at the plasma membrane and
intracellular compartments in both HEK293 and HeLa cells,
whereas when complemented with the purified and cell-imper-
meant-modified 18-kDa fragment of NLuc (LgBiT), exclusive
membrane localization was observed for cells expressing
genome-edited HiBiT/CXCR4 in HEK293 cells (Figure 1F). In
agreement with reported intracellular localization of ACKR3
(Rajagopal et al., 2010), NLuc/ACKR3 expression was primarily
observed clustered in a perinuclear region in genome-edited
HeLa cells (Figure 1G).
NanoBRET Ligand Binding at CXCR4 and ACKR3
Chemokine Receptors
Previously we used NanoBRET to investigate ligand binding to
exogenously expressed GPCRs (Stoddart et al., 2015), receptor
tyrosine kinases (Kilpatrick et al., 2017), and more recently ligand
binding to adenosine A2B receptors expressed under endogenous
promotion (White et al., 2019). Here, we have further expanded on
these approaches and demonstrate fluorescent ligand binding at
genome-edited NLuc/CXCR4 (Figure 2; HEK293 and HeLa cells)
and NLuc/ACKR3 (Figure 3; HeLa cells) chemokine receptors.
Initial studies confirmed our previous reports (Caspar et al.,
2018) of clear saturable specific binding of CXCL12-AF647 to
membranes from HEK293 cells stably expressing exogenous
NLuc/CXCR4 (Figure 2A; pKd = 7.55 ± 0.06, n = 3). In addition,
we demonstrated CXCL12-AF647 binding to exogenous NLuc/
ACKR3 stably expressed in HEK293 cells (Figure 3A; pKd =
8.12 ± 0.10, n = 5) as well as membranes (Figure 3B; pKd =
8.83 ± 0.06, n = 4). Exemplifying the high assay sensitivity of
NanoBRET ligand binding, clear saturable ligand binding was
achieved at the low levels of expression found in all clonal
genome-edited cell lines (Figures 2 and 3). Similarly, AMD3100
competition with CXCL12-AF647 for binding to genome-edited
NLuc/CXCR4 receptors was able to be detected in a non-clonal
pool of HEK293 cells, estimated <5% positive, transiently trans-
fected with Cas9 guides and NLuc/CXCR4 repair templates (Fig-
ure S2; pIC50 = 7.56 ± 0.22, n = 5).
The level of receptor expression and/or oligomerization has
the potential to modulate aspects of receptor function. Indeed,
CXCR4 and ACKR3 are capable of forming oligomeric com-
plexes that modulate signaling (Decaillot et al., 2011) and
GPCR oligomer formation can lead to negative cooperativity
between protomers (May et al., 2011; Sohy et al., 2009). To
investigate possible effects of receptor expression level or
Figure 1. Analysis of Protein Expression Following Genome Editing
(A) CXCR4 mRNA expression in wild-type HEK293 cells or HEK293 clones expressing genome-edited NLuc/CXCR4, CXCR4/LgBiT, or CXCR4/LgBiT and
ARRB2/SmBiT (dual).
(B) CXCR4 mRNA expression in wild-type HeLa cells or HeLa clones expressing genome-edited NLuc/CXCR4.
(C) ARRB2 mRNA expression in wild-type HEK293 cells or HEK293 clones expressing genome-edited ARRB2/SmBiT, or ARRB2/SmBiT and CXCR4/LgBiT
(dual). Relative mRNA level, normalized to BM2 expression. Bars represent mean ± SEM of three cell passages of a single clone performed in triplicate.
(D–G) Visualization of genome-edited receptor localization in HEK293 and HeLa cells using a bioluminescence LV200 Olympus microscope. (D) HEK293 and (E)
HeLa cells expressing genome-edited NLuc/CXCR4, (F) HEK293 cells expressing genome-edited HiBiT/CXCR4 complemented with LgBiT and (G) HeLa cells
expressing genome-edited NLuc/ACKR3. White arrow heads (D–F) indicate predominant expression at the plasma membrane of luciferase-tagged CXCR4, red
arrow heads (G) indicate NLuc/ACKR3 expression in cytosolic compartments. Images were acquired by capturing total luminescence for 90 s.
Scale bar represents 20 mm. See Figure S1.
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differences in expression of our genetically engineered and
exogenous cells lines. Quantification of NLuc-tagged receptor
expression (Figure 2E) showed 75- and 60-fold greater
NLuc/CXCR4 expression in the exogenous cell lines than
genome-edited HEK293 or HeLa cells, respectively. Similarly,
exogenous expression of NLuc/ACKR3 in stable HEK293 cells,
which lack endogenous ACKR3 (Figure S1B), was 400-fold
greater than that seen in genome-edited HeLa cells (Figure 3D).
However, we observed no difference in the binding affinity of
CXCL12-AF647 to NLuc/CXCR4 expressed in genome-editedHEK293 cells with low levels of expression (Figure 2B; pKd =
7.50 ± 0.04, n = 3) or in genome-edited HeLa cells (Figure 2C;
pKd = 7.58 ± 0.04, n = 4), where ACKR3 is also endogenously
expressed, compared with HEK293 cell membranes ex-
pressing exogenous NLuc/CXCR4 (Figure 2A). Likewise, we
only observed small differences in the affinities (Table 1) of
CXCL12-AF647 binding to NLuc/ACKR3 when expressed exog-
enously in live HEK293 cells (Figure 3A; pKd = 8.12 ± 0.10, n = 5)
or membranes (Figure 3B; pKd = 8.83 ± 0.06, n = 4) or expressed
in genome-edited HeLa cells (Figure 3C; pKd = 8.77 ± 0.11,
n = 6). This small difference in affinity may be related to the abilityCell Chemical Biology 27, 1–12, April 16, 2020 3
Figure 2. Determination of the Binding Af-
finity of CXCL12-AF647 at NLuc/CXCR4
(A–D) NanoBRET saturation ligand binding curves
obtained in (A) membrane preparations from
HEK293 cells exogenously expressing NLuc/
CXCR4 (B) live HEK293 cells expressing genome-
edited NLuc/CXCR4 (C) live HeLa cells expressing
genome-edited NLuc/CXCR4 or (D) live HEK293
cells expressing genome-edited HiBiT/CXCR4
complemented with LgBiT. Cells or membranes
were incubated with increasing concentrations of
CXCL12-AF647 in the absence (black circles) or
presence (white circles) of AMD3100 (10 mM) for
1 h at 37C. Data shown are mean ± SEM and are
representative of three or four independent ex-
periments performed in duplicate for (A and B) and
(C and D), respectively.
(E) Quantification of NLuc/CXCR4 expression by
linear regression (F), as described in the STAR
Methods, using membrane preparations made
from HEK293 cells exogenously expressing NLuc/
CXCR4 (NLuc/CXCR4 TG, black bar), HEK293
cells expressing genome-edited NLuc/CXCR4
(NLuc/CXCR4 HEK, gray bar), or HeLa cells ex-
pressing genome-edited NLuc/CXCR4 (NLuc/
CXCR4 HeLa, white bar).
Data shown are (F) mean ± SEM or (E) represen-
tative of five individual experiments performed in
triplicate (see Figure S2).
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Finally, the use of fluorescent agonists in live cell NanoBRET
ligand binding assays can result in internalization of the recep-
tor. To localize binding to receptors at the plasma membrane in
a live cell assay, we used HEK293 cells expressing genome-
edited HiBiT/CXCR4 with functional NLuc generated following
ligand equilibration by complementation of the HiBiT-tagged
receptor with exogenously added cell-impermeant LgBiT. This
limited luminescence (Figure 1F) and therefore observable
NanoBRET signal to receptors remaining at the plasma mem-
brane. However, no difference in the binding affinity of
CXCL12-AF647 to HiBiT/CXCR4 compared with NLuc/CXCR4
(Figure 2D; pKd = 7.49 ± 0.05, n = 4) was observed.
Measurement of CXCR4 Recruitment of b-Arrestin2 by
NanoBiT Complementation
Following ligand binding, GPCRs interact with a number of intra-
cellular proteins that modulate as well as elicit their function.4 Cell Chemical Biology 27, 1–12, April 16, 2020Among these, b-arrestin scaffolding pro-
teins have been extensively studied and
regulate GPCR internalization as well as
intracellular signaling. However, methods
used to investigate live cell b-arrestin
recruitment to a GPCR, and protein-pro-
tein interactions in general, largely require
the use of a reporter protein that is exog-
enously overexpressed. We have previ-
ously investigated receptor-b-arrestin2
interactions using BRET where one pro-
tein fused to NLuc was expressed underendogenous promotion; however, we could not observe interac-
tions between two endogenously expressed proteins. Here, we
sought to determine if endogenous CXCR4-b-arrestin2 interac-
tions could be investigated using genome-edited proteins and
the low-affinity NanoBiT (SmBiT-LgBiT, Kd  190 mM) comple-
mentation system. In HEK293 cells expressing genome-edited
b-arrestin2/SmBiT transiently transfected with CXCR4/LgBiT
(Figures 4A and 4B), HEK293 cells expressing genome-edited
CXCR4/LgBiT transiently transfected with b-arrestin2/SmBiT
(Figures 4C and 4D), HEK293 cells expressing both genome-edi-
ted CXCR4/LgBiT and b-arrestin2/SmBiT (Figures 4E and 4F)
and HEK293 cells expressing transiently transfected CXCR4/
LgBiT and b-arrestin2/SmBiT (Figures 4G and 4H), we observed
an increase in luminescence following CXCL12 (300 nM) addition
that was inhibited by AMD3100 (1 mM). Recruitment of genome-
edited b-arrestin2/SmBiT to genome-edited or transiently ex-
pressed CXCR4/LgBiT could be inhibited by overexpression of
unlabeled b-arrestin2/Halotag (Figure S3), indicative of a specific
protein-protein interaction. Basal luminescence varied between
Figure 3. Determination of the Binding Affinity of CXCL12-AF647 at NLuc/ACKR3
(A–C) NanoBRET saturation ligand binding curves obtained in (A) live HEK293 cells exogenously expressing NLuc/ACKR3, (B) membrane preparations from
HEK293 cells exogenously expressing NLuc/ACKR3, and (C) live HeLa cells expressing genome-edited NLuc/ACKR3. Cells or membranes were incubated
with increasing concentrations of CXCL12-AF647 in the absence (black circles) or presence (white circles) of CXCL11 (10 mM) for 1 h at 37C. Data shown are
mean ± SEM and are representative of five (A), four (B), and six (C) experiments performed in duplicate.
(D) Quantification of NLuc/ACKR3 expression by linear regression, as described in the STAR Methods, using membrane preparations made from HEK293 cells
exogenously expressing NLuc/ACKR3 (NLuc/ACKR3 TG, black bar) or HeLa cells expressing genome-edited NLuc/ACKR3 (NLuc/ACKR3 CRISPR, gray bar).
Data shown are mean ± SEM of five individual experiments performed in triplicate.
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and constitutive b-arrestin2/SmBiT recruitment to CXCR4/LgBiT
dependent on the relative levels of receptor and effector expres-
sion (Figure S4A). As expected, the greatest basal luminescence
in genome-edited HEK293 cells was observed when CXCR4/
LgBiT was in excess of b-arrestin2/SmBiT (Figure S4A) where
constitutive CXCR4 activity would be highest. Similarly, in
HEK293 cells expressing genome-edited CXCR4/LgBiT tran-
siently transfected with b-arrestin2/SmBiT, where there was an
excess of b-arrestin2 relative to receptor, analysis of the kinetic
profile of recruitment showed faster recruitment (t1/2, time in
minutes to half maximum response ± SEM: 1.89 ± 0.17 min,
n = 6) compared with HEK293 cells expressing genome-edited
b-arrestin2/SmBiT and transiently expressed CXCR4/LgBiT
(t1/2: 4.62 ± 0.39 min, p < 0.05, n = 7), HEK293 cells expressing
both genome-edited CXCR4/LgBiT and genome-edited b-ar-
restin2/SmBiT (t1/2: 3.11 ± 0.12 min, n = 8) or HEK293 cells tran-
siently expressing CXCR4/LgBiT and b-arrestin2/SmBiT (t1/2:
5.27 ± 0.52 min, p < 0.01, n = 7). In contrast to the other assayconfigurations, cells expressing genome-edited CXCR4/LgBiT
and transiently expressed b-arrestin2/SmBiT showed a unique
transient recruitment profile (Figure 4C). CXCL12 induced a
concentration-dependent increase in luminescence in all assay
configurations with similar potency when measured approxi-
mately 5 min after ligand addition (Figures 4B, 4D, 4F and, 4H:
pEC50 = 7.48 ± 0.04, 7.69 ± 0.14, 7.16 ± 0.17, and 7.66 ± 0.23,
n = 6–8, respectively).
Using HiBiT-Tagged Receptors to Investigate Cell
Surface Expression and CXCR4 Conformational
Changes
Following agonist-induced receptor activation and b-arrestin
recruitment, CXCR4, like many GPCRs, is internalized and traf-
ficked via endosomes to lysosomes for degradation or recycled
back to the plasma membrane (Magalhaes et al., 2012). Because
of the cell-impermeant nature of purified LgBiT, ligand-induced
changes in cell surface receptor expression and/or internalization
should be able to be monitored by measuring the extent ofCell Chemical Biology 27, 1–12, April 16, 2020 5
Table 1. Binding Affinities of CXCL12-AF647 at NLuc/CXCR4 or
NLuc/ACKR3 Measured by NanoBRET
Cell Line or
Membrane
Preparation pKd n
Tagged Receptor
Expression Level
(fmol/mg membrane)b
TG NLuc/CXCR4 (7.15 ± 0.04)a – –
TG NLuc/CXCR4
membranes
7.55 ± 0.06
(7.61 ± 0.10)a
3 90.67 ± 17.06
CRISPR NLuc/
CXCR4 HEK
7.50 ± 0.04 3 1.45 ± 0.43
CRISPR NLuc/
CXCR4 HeLa
7.58 ± 0.04 4 2.12 ± 0.95
CRISPR HiBiT/
CXCR4
7.49 ± 0.05 4 ND
TG NLuc/ACKR3
HEK***
8.12 ± 0.10 5 –
TG NLuc/ACKR3
membranes
8.83 ± 0.06 4 52.9 ± 17.4
CRISPR NLuc/
ACKR3 HeLa
8.77 ± 0.11 6 0.27 ± 0.14
TG cell lines indicate cells expressing transgenic exogenously expressed
receptors, CRISPR cells lines indicate those expressing a genome-edited
receptor under endogenous promotion. TG NLuc/CXCR4 or TG NLuc/
ACKR3 membranes made from the respective cell lines. ***p < 0.001
was determined by a one-way ANOVA and indicate a significant differ-
ence between assay configurations in the binding affinity of CXCL12-
AF647 to NLuc/ACKR3.
apKd values in parentheses from Caspar et al. (2018).
bValues indicatemean ±SEMof five independent experiments performed
in triplicate.
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determine the level of cell surface receptors) after incubation for
different times with agonist. This assay has been described previ-
ously for internalization of Galanin (Reyes-Alcaraz et al., 2018) and
Orexin (Rouault et al., 2017) receptors, but to our knowledge has
not been applied to investigate CXCR4 internalization. We initially
established the assay using HEK293 cells stably overexpressing
HiBiT/CXCR4 (Figure 5A) and in live cells observed a concentra-
tion-dependent decrease in luminescence following application
of CXCL12 (pEC50 = 8.69± 0.06, n = 5), consistentwith a decrease
in cell surface expression and internalization. Surprisingly inhibi-
tors of CXCR4, AMD3100 (pEC50 = 6.99 ± 0.22, n = 5) and IT1t
(pEC50 = 7.55± 0.11, n = 5), but not the adenosine receptor antag-
onist XAC (xanthine amine congener), resulted in a concentration-
dependent increase in luminescence suggestive of an increase in
cell surface expression, potentially due to constitutive trafficking
to the membrane. Taking advantage of our genome-edited Hi-
BiT/CXCR4 HEK293 cells (Figure 5B) we confirmed the increase
in luminescence mediated by AMD3100 (pEC50 = 6.91 ± 0.14,
n = 5) and IT1t (pEC50 = 7.46 ± 0.07, n = 5) was not a consequence
of receptor overexpression. Furthermore, CXCL12 (pEC50 =
8.46 ± 0.20, n = 5)-mediated receptor internalization has been
observed at HiBiT/CXCR4 expressed under endogenous promo-
tion confirming the assay could be used at receptors expressed
under endogenous promotion.
It has previously been shown that CXCR4 function can
be modulated by constitutive receptor internalization and traf-6 Cell Chemical Biology 27, 1–12, April 16, 2020ficking. Indeed, inhibition of endocytosis increases CXCR4
cell surface expression in a manner independent of CXCL12
(Pelekanos et al., 2014), whereas CXCL12 changes the consti-
tutive dynamics of CXCR4 at the plasma membrane causing
receptor immobilization and/or accumulation in lipid rafts that
enhances signaling (Wysoczynski et al., 2005). Furthermore, it
has been proposed that increasing constitutive CXCR4 cell sur-
face expression may be a useful strategy to enhance migration
of systemically transplanted cells (Pelekanos et al., 2014). To
establish if the model could be used to better understand the
effects of constitutive CXCR4 trafficking, we first sought to
confirm that constitutive trafficking was indeed being observed.
In CXCL12 knockout HEK293 cells (CXCL12-KO, Figure S5A)
transiently transfected with HiBiT/CXCR4, application of
AMD3100 produced an increase in luminescence (Figure S5B),
indicating that the effect was not driven by endogenous
CXCL12. However, in HEK293 cells expressing genome-
edited HiBiT/CXCR4 (Figure 5C), kinetic analysis showed that
AMD3100 and IT1t mediated a rapid, but saturable, increase
in luminescence suggestive of a non-active-trafficking process.
To further rule out active forward receptor trafficking or recep-
tor internalization being involved in the change in luminescence
we used saponin-permeabilized membrane preparations from
HEK293 cells exogenously expressing HiBiT/CXCR4 (Figures
5D and 5E). Here, despite an absence of receptor trafficking
we observed a similar concentration-dependent saturable in-
crease in luminescence mediated by AMD3100 (pEC50 =
6.98 ± 0.39, n = 5) and IT1t (pEC50 = 8.38 ± 0.02, n = 5). More-
over, in contrast to live cells, CXCL12 resulted in a small in-
crease in luminescence in membrane preparations but inhibited
the increase in luminescence mediated by AMD3100 (1 mM,
Figure 5F; p < 0.01 for 100 nM and 1 mM CXCL12), therefore,
indicating that the ligand-mediated effects were due to specific
changes in CXCR4. However, together, these data were not
supportive of the assay configuration simply reporting on
antagonist-mediated changes in constitutive CXCR4 trafficking
in live cells.
It is known that small-molecule inhibitors such as AMD3100
induce conformational rearrangement of the extracellular do-
mains of CXCR4 that can result in modulation of monoclonal
antibody binding, despite themselves binding within the trans-
membrane bundle (Carnec et al., 2005; Rosenkilde et al., 2004).
Therefore, we hypothesized that under basal conditions the
extracellular conformation of CXCR4 resulted in steric hin-
drance and that application of AMD3100 or IT1t resulted in a
conformation more favourable for HiBiT-LgBiT complementa-
tion. In genome-edited HEK293 cells expressing HiBiT/
CXCR4, the affinity of complementation with purified LgBiT
(Figure 6A; Kd = 229.8 ± 37.2 nM) was lower than that observed
in genome-edited HEK293 cells expressing b2-adrenoceptors
tagged on the N-terminal with HiBiT (HiBiT/b2-adrenceptor)
(Figure 6D; Kd = 54.5 ± 14.6 nM, p < 0.05, one-way ANOVA
with Dunnett’s multiple comparisons test). Furthermore,
AMD3100 (10 mM) resulted in an increase in the affinity of Hi-
BiT/CXCR4-LgBiT complementation in cells (Figure 6A; Kd =
58.5 ± 9.6 nM, n = 7, p < 0.01) and membranes (Figure 6B;
Kd = 180 ± 16.1 nM and 115.1 ± 9.5 nM in the absence and
presence of AMD3100, respectively, n = 6, p < 0.01) but not
for complementation of purified HiBiT to purified LgBiT
Figure 4. Investigation of b-Arrestin2/
SmBiT Recruitment to CXCR4/LgBiT in
Genome-Edited HEK293 Cells
HEK293 cells expressing (A and B) genome-edited
b-arrestin2/SmBiT transiently transfected with
CXCR4/LgBiT (CRISPR b-arr2/SmBiT), (C and D)
genome-edited CXCR4/LgBiT transiently trans-
fected with b-arrestin2/SmBiT (CRISPR CXCR4/
LgBiT), (E and F) both genome-edited CXCR4/
LgBiT and genome-edited b-arrestin2/SmBiT
(Dual CRISPR), or (G and H) HEK293 cells ex-
pressing transiently transfected CXCR4/LgBiT and
b-arrestin2/SmBiT (dual exogenous), were stimu-
lated with 300 nM CXCL12 (A, C, E, and G) or
increasing concentrations of CXCL12 (0.3–300 nM)
(B, D, F, and H) in the absence (black squares and
circles) or presence (white squares and circles) of
1 mMAM3100. Points represent mean ± SEM of six
(C and D), seven (A, B, E, and F) or eight (G and H)
individual experiments performed in triplicate.
pEC50 values stated were calculated from
response at approximately 5 min after ligand
addition. Baseline-corrected luminescence calcu-
lated as described in the STAR Methods (see
Figures S3 and S4).
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the absence and presence of AMD3100, respectively). To
further investigate if these effects were specific to HiBiT/
CXCR4, we used HEK293 cells expressing exogenous HiBiT/
ACKR3 (Figure S6A) and observed a concentration-dependent
increase in luminescence following application of CXCL11 or
CXCL12 (pEC50 = 7.48 ± 0.11 and pEC50 = 8.23 ± 0.05, n =
5, respectively). In HEK293 cells expressing genome-edited Hi-
BiT/b2-adrenoceptors (Figure S6B), application of isoprenaline
(pEC50 = 6.82 ± 0.31, n = 5) but not propranolol resulted in a
concentration-dependent decrease in luminescence indicative
of internalization. These results demonstrate that for some re-
ceptors nanoluciferase complementation assays can be config-
ured to investigate ligand-induced conformational changes.
DISCUSSION
Using CRISPR/Cas9-mediated homology-directed repair, we
have expanded the use of genome-edited NanoBRET andNano-Cell CBiT techniques to investigate multiple
aspects of GPCR function. However,
analysis of mRNA expression following
engineering showed a variable change in
CXCR4 expression in some clonal lines.
We have reported changes in expression
following genome editing that depends
on the tag sequence (Khan et al., 2019);
however, here this appears unlikely
since the two HEK293 cell lines express-
ing genome-edited CXCR4/LgBiT did
not show comparable effects, and anal-
ysis of ARRB2 expression showed no
observable differences following editing.An alternative explanation is that changes in expression are
due to on/off-target effects of the editing (Zhang et al., 2015),
or due to the subsequent cloning procedure resulting in amplifi-
cation of a founder cell with acquired changes to the cellular pro-
teome. Indeed, such compensatory rewiring has been described
by other groups in clonal knockout cells engineered with
CRISPR/Cas9 (Luttrell et al., 2018). Furthermore, all of the
genome-edited clones that we generated were heterozygous
for the insert, therefore differences in expression also accounts
for changes in untagged alleles. Although we were only able to
perform these analyses on a single clonal cell line from each
configuration, these data suggest that changes in expression
are specific to the individual genome-edited clonal line. Despite
this, the changes in expression in genome-edited cells are rela-
tively minor compared with the level of overexpression that
occurs when receptors are expressed exogenously.
Determining the parameters of ligand-receptor binding, i.e.,
ligand affinity for a receptor, underpins the pharmacological un-
derstanding of receptor function. NanoBRET ligand binding is a
homogeneous assay capable of investigating ligand binding athemical Biology 27, 1–12, April 16, 2020 7
Figure 5. Using HiBiT-tagged CXCR4 to
Investigate Cell Surface Expression and/or
Conformational Changes
(A–D) HEK293 cells expressing (A) exogenous or
(B) genome-edited HiBiT/CXCR4 were incubated
in the absence or presence of increasing concen-
trations of AMD3100 (black circles), IT1t (white
circles), CXCL12 (black squares), or XAC (white
squares) for 1 h at 37C and luminescence
measured 30 min following addition of purified
LgBiT (10 nM) and furimazine (10 mM). Kinetic
analysis of the change in luminescence mediated
by addition of AMD3100 (1 mM, black circles), IT1t
(1 mM, white circles), CXCL12 (1 mM, black
squares), or XAC (1 mM, white squares) in (C)
HEK293 cells expressing genome-edited HiBiT/
CXCR4 or (D) using membrane preparations from
HEK293 cells exogenously expressing HiBiT/
CXCR4, both pre-incubated with 10 nM purified
LgBiT.
(E) AMD3100 (black circles), IT1t (white circles),
CXCL12 (black squares), or XAC (white squares)
concentration-response curves using membrane
preparations from HEK293 cells exogenously ex-
pressing HiBiT/CXCR4 complemented with LgBiT.
(F) Concentration-dependent inhibition of the
AMD3100-mediated increase in luminescence by
CXCL12 using membrane preparations from
HEK293 cells exogenously expressing HiBiT/
CXCR4 complemented with LgbiT and pre-incu-
bated with 10 nM purified LgBiT. Points represent
mean ± SEMof four (D), five (A, B, and, E), six (C), or
eight (F) experiments performed in triplicate.
Baseline-corrected luminescence calculated as
described in the STAR Methods. **p < 0.01. Sta-
tistical analysis by one-way ANOVA with a Dun-
nett’s multiple comparisons test (see Figures S5
and S6).
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2015;White et al., 2019). Here, we further demonstrate the sensi-
tivity of NanoBRET to investigate fluorescent ligand binding at
both exogenous and genome-edited chemokine receptors
across a range of expression levels and on a non-clonal pool
of cells. This latter approach is analogous to a plasmid-based
transient transfection and is complementary to that described
previously for NanoBiT tagging using purified Cas9 and single-
stranded oligo DNA nucleotides in that it provides a rapid
method for generating assayable genome-edited cells (Schwinn
et al., 2018). Since no clonal isolation is required, any effects on
the cellular phenotype is limited and the approach may be a
useful strategy for editing primary cells with finite population
doubling times.
Because of the ratiometric nature of BRET, the number of
binding sites, and therefore protein expression levels, cannot
be directly determined from NanoBRET saturation binding as-
says. However, we demonstrate that NLuc enzymatic activity,
reported to be linear over eight orders of magnitude (Schwinn
et al., 2018), can be used to quantify luciferase-tagged receptor
expression and therefore may be a useful supplement to8 Cell Chemical Biology 27, 1–12, April 16, 2020NanoBRET binding assays. However, untagged receptors in het-
erozygous genome-edited cell lines or endogenous receptors in
exogenously expressed cell lines are not detected. Similarly,
quantification of NLuc-tagged receptor expression in live cell
systems would detect receptors potentially inaccessible to
some ligands such as those found in intracellular compartments.
The function of CXCR4 can be influenced by spatiotemporal
factors such as cellular compartmentalization (Wysoczynski
et al., 2005) as well as by the absence, presence, or relative stoi-
chiometry of interacting partners found in the cellular proteome
(Heuninck et al., 2019). Here, we observed no difference in the
binding affinity of CXCL12-AF647 for NLuc/CXCR4, despite the
differences in NanoBRET ligand binding assays used, i.e., high
or low expression of CXCR4, the absence or presence of
ACKR3, or where the effects of agonist-induced internalization
of CXCR4 were removed, indicating that the variables we tested
have little impact on CXCL12 binding to CXCR4. Indeed, while
CXCR4 is thought to form homo/hetero-dimers with CCR2,
CCR5, CXCR3, and ACKR3, modulation of ligand binding by
cooperative and/or allosteric interactions has primarily been re-
ported for CCR2, CCR5, and CXCR3 (Sohy et al., 2009; Watts
Figure 6. Investigation of the Effect of Protein Fusion on the Affinity of HiBiT-LgBiT Complementation
(A–C) HEK293 cells expressing genome-edited HiBiT/CXCR4 (black symbols) or wild-type HEK293 cells (white squares) (A), membranes from HEK293 cells
expressing genome-edited HiBiT/CXCR4 (black symbols) and wild-type HEK293 cells (white squares) (B), or purified HiBiT control protein (black symbols) were
incubated with increasing concentrations of LgBiT in the absence (black circles) or presence (black squares) of AMD3100 (10 mM) (C).
(D) HEK293 cells expressing genome-edited HiBiT/b2-adrenoceptor (downward triangles) or wild-type HEK293 cells (white squares) were incubated with
increasing concentrations of purified LgBiT. Points are mean ± SEM and are representative of five (C and D), six (B), or seven (A) experiments performed in
triplicate.
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detectable levels in HEK293 or HeLa cells (Thul et al., 2017).
The effect of ACKR3 interactions with CXCR4 appear tomanifest
in differences in signaling (Decaillot et al., 2011; Levoye et al.,
2009). It is also possible that further intervention, e.g., activation
of ACKR3, is required to observe any allosteric or cooperative
differences in CXCL12 binding to CXCR4.
In contrast to ligand binding, the context in which a receptor
is found can drastically affect signaling, with variations in the
cellular proteome influencing function. However, many assays
used to study receptor signaling disrupt the normal cellular bal-
ance by overexpression of the receptor or interacting effectors.
A prototypical example of this is the use of overexpression
fusion proteins to probe recruitment of b-arrestins to GPCRs,
which can be used to investigate receptor desensitization, G
protein-independent signaling, and establish biased agonism.
However, b-arrestins are active participants in GPCR regulation
with overexpression or deletion modulating the duration and
magnitude of GPCR-mediated G protein signaling (Luttrell
et al., 2018; Smith et al., 2019) as well as modulation of ligand
binding (Gurevich et al., 1997). Using NanoBiT complementa-tion, we have directly compared the effect of different combina-
tions of genome-edited and exogenous proteins on the kinetic
profile of ligand-induced b-arrestin2/SmBiT recruitment to
CXCR4/LgBiT. The kinetic profiles from each configuration
were obtained from a clonal line derived from a single
heterozygously tagged cell, therefore, untagged CXCR4 and/
or b-arrestin2 present, will result in non-productive interactions
occurring. In addition, here we tagged both CXCR4 and b-ar-
restin2 on their respective C termini, which may restrict the
ability of the two proteins to interact or alter specific geometry
of the interaction compared with untagged proteins. Although
both these factors may influence the profile of recruitment,
the kinetics from the singularly genome-edited assay configura-
tions are consistent with those observed previously in genome-
edited NanoBRET assays (White et al., 2017). Notably, where
CXCR4/LgBiT was expressed in excess to b-arrestin2/SmBiT
the CXCL12-mediated increase in luminescence was slower
than where b-arrestin2/SmBiT was in excess, suggesting a
rate-limiting step when CXCR4 was overexpressed. Plausibly
this is due to high exogenous CXCR4 expression overwhelming
the capacity of endogenous GRKs to phosphorylate (BusilloCell Chemical Biology 27, 1–12, April 16, 2020 9
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down the subsequent kinetics of b-arrestin recruitment.
Conversely, where b-arrestin2/SmBiT was in excess of
CXCR4/LgBiT, we observed a rapid ligand-induced lumines-
cence peak followed by a rapid decline and plateau, suggesting
association then dissociation of CXCR4/LgBiT and b-arrestin2/
SmBiT. b-Arrestins play a role in targeting CXCR4 for lysosomal
degradation (Malik and Marchese, 2010), and in addition we
have previously observed internalization and trafficking of
genome-edited CXCR4 to lysosomes within a few minutes of
agonist simulation (White et al., 2017). This suggests that the
transient recruitment profile may be due to increased degrada-
tion of CXCR4 where b-arrestin2/SmBiT is overexpressed.
Here, our data also highlight care must be taken if using the ki-
netic profile of b-arrestin recruitment to determine the stability
of GPCR-b-arrestin interactions or designating subtle differ-
ences in the kinetic profiles of b-arrestin recruitment to GPCRs
since they may be attributable to changes in protein expres-
sion. Finally, propagation of system/assay effects need to be
controlled when examining biased GPCR agonism. Sources
of error may include, variation in the receptor-effector levels
due to the choice of cellular background and/or assay used,
e.g., the use of overexpressed b-arrestin or G protein biosen-
sors versus measurement of G protein signaling mediated by
endogenous G proteins, as well as the kinetics of a signaling
pathway (Klein Herenbrink et al., 2016; Galandrin et al., 2016).
Coupling luciferase competition techniques with CRISPR/
Cas9 genome editing as we have done here, which allows
interactions between two natively expressed proteins to be
observed, may therefore better recapitulate the ‘‘native’’ ki-
netics and stoichiometry of these protein-protein interactions
when investigating ligand bias.
Following b-arrestin recruitment, GPCRs are internalized and
investigating these processes are important for understanding
receptor desensitization and recycling. Here, using cell-imper-
meant LgBiT and genome-edited HiBiT/CXCR4 or HiBiT/b2-
adrenoceptors we demonstrate that receptor internalization
can be inferred from agonist-mediated decreases in lumines-
cence, thereby confirming previous studies using the same
assay format with overexpressed receptors. Unlike bystander
BRET assays, however, which can monitor kinetics of receptor
internalization, cell surface expression was determined by
HiBiT/Receptor-LgBiT complementation at a single time point
after agonist stimulation. Therefore, the decrease in lumines-
cence is the sum of internalization, forward trafficking, and
receptor recycling. Indeed, in our hands, kinetic analysis of the
effect of CXCL12 on HiBiT/CXCR4 cell surface expression in
live cell assay shows CXCL12 induced a small increase in lumi-
nescence before gradually declining, which would be in agree-
ment with CXCL12 accumulation/compartmentalization of
CXCR4 in the plasma membrane before internalization (Wysoc-
zynski et al., 2005; White et al., 2017).
In addition, we demonstrate that receptors tagged with HiBiT
on the N terminus do not necessarily report purely on ligand-
induced changes in cell surface expression but in a novel assay
configuration potentially also on extracellular conformational
changes of exogenous or genome-edited receptors. Lumines-
cence output is reliant on HiBiT-LgBiT complementation but,
as seen in Figure 6, the affinity of HiBiT for purified LgBiT can10 Cell Chemical Biology 27, 1–12, April 16, 2020be altered by fusion to a receptor or protein. These differences
in affinity are likely due to steric hindrance imparted by the pro-
tein of interest. It follows that, and as we demonstrate for HiBiT/
CXCR4, ligands that can modulate the conformation of a protein
may, therefore, change the affinity of HiBiT-LgBiT complementa-
tion. Although these results were surprising and are an additional
caveat to HiBiT-based internalization assays, differential
NanoBiT affinity following fusion to a protein is not unexpected
and can be exploited to investigate the effect of ligand binding
on receptor conformation. Indeed, our results support the notion
that AMD3100, in part, prevents binding of extracellular binders
e.g., antibodies, HIV, as well as CXCL12 to CXCR4 by inducing
conformational rearrangement of the extracellular domains
despite itself binding in the transmembrane bundle (Rosenkilde
et al., 2004). Furthermore, the agonist-mediated increase in lumi-
nescence at HiBiT-tagged ACKR3 likely suggests that there is a
change in HiBiT-LgBiT complementation affinity at ACKR3 as
well as different N-terminal orientation to CXCR4 and supports
the observations of different CXCL12 binding modes between
the two receptors (Benredjem et al., 2017; Gustavsson
et al., 2017).
A final consideration for a change in affinity of tagged-HiBiT for
LgBiT is its subsequent use to measure protein expression.
Quantification by enzymatic activity assumes luminescence
generated by the HiBiT-tagged protein is proportional to that
generated by purified HiBiT (when complemented to a saturating
concentration of LgBiT). However, as the affinity of tagged-HiBiT
for LgBiT approaches or exceeds (as seen with HiBiT/CXCR4),
the concentration of purified LgBiT that can be feasibly used,
the assay underestimates the number of HiBiT-tagged proteins.
Therefore, to ensure accurate protein quantification by this
method, the affinity of tagged-HiBiT for LgBiT may need to be
empirically determined for individual proteins and assay condi-
tions or tag placement subsequently modified.
SIGNIFICANCE
In summary, we demonstrate the use of CRISPR/Cas9
genome editing to investigate multiple aspects of chemo-
kine receptor function via NanoBRET- or NanoBiT-based
assayswhere the proteins are expressed under endogenous
promotion. We also show fluorescent ligand binding to
genome-edited chemokine receptors and that nanolucifer-
ase complementation can be used to monitor extracellular
conformational changes following ligand binding in a live
cell assay. In addition, we demonstrate that nanoluciferase
complementation can be used to monitor ligand-induced
receptor protein interactions where both partners are ex-
pressed under endogenous transcriptional control. These
techniques have allowed us to examine the effect of protein
expression on GPCR function and we show that the kinetic
profile of b-arrestin2 recruitment to CXCR4 is dependent
on the relative level of expression between the two proteins.
These genome-editing techniques have the potential to
generate cellular systems that more closely represent the
‘‘native’’ cellular environment, with minimal disruption to
the normal cellular stoichiometry. Therefore these ap-
proaches may represent better models to investigate G pro-
tein-coupled receptor function and to understand how
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Chemicals, Peptides, and Recombinant Proteins
AMD3100 Selleckchem Cat # S8030
Covine serum albumin (Protease-free) Sigma Aldrich Cat# 03117332001
CXCL11 Preprotech Cat# 300-46
CXCL12 Preprotech Cat# 300-28A
CXCL12-AF647 Almac Cat# CAF-11
N,N’-Dicyclohexylcarbamimidothioic acid (5,6-
dihydro-6,6-dimethylimidazo[2,1-b]thiazol-3-yl)methyl
ester dihydrochloride (IT1t)
Tocris Cat# 4596
Dulbecco’s Modified Eagle’s Medium Sigma Aldrich Cat# D6429
Fetal Bovine Serum Sigma Aldrich Cat# F2442
Fugene HD Promega (Wisconsin, USA) Cat# E2311
Geneticin (G418) ThermoFisher Cat# 10131035
HiBiT-Halotag, control peptide Promega (Wisconsin, USA) Cat# N3010
Isoprenaline hydrochloride Sigma Aldrich Cat# I6504
Phosphate Buffered Saline (PBS) Sigma Aldrich Cat# D8537
Poly-D-Lysine hydrobromide Sigma Aldrich Cat# P6407
(±)-propranolol hydrochloride Sigma Aldrich Cat# P0884
Purified LgBiT Promega (Wisconsin, USA) Cat# N401A
Purified full length NLuc Promega (Wisconsin, USA) Gift from Matt Robers (Promega)
Puromycin dihydrochloride from Streptomyces alboniger Sigma Aldrich Cat# P8833
Saponin Sigma Aldrich Cat# 84510
Xanthine amine congener (XAC) Sigma Aldrich Cat# X103
Critical Commercial Assays
Maxima First Strand cDNA Synthesis Kit Thermo Fisher Scientific Cat# K1641
Nano-Glo luciferase assay system (Furimazine) Promega (Wisconsin, USA) Cat# N1130
Pierce bicinchoninic acid protein assay kit Thermo Fisher Scientific Cat# 23225
PowerUp SYBR Green Master Mix Thermo Fisher Scientific Cat# A25742
ReliaPrep RNA extraction kit Promega Corporation
(Wisconsin,USA)
Cat# Z6010
Hs_B2M_1_SQ QuantiTect Primer Assay Qiagen Cat# QT00088935
Experimental Models: Cell Lines
Human HEK293FT cells (female) Life Technologies Cat# R70007
Human HeLa cells (female) Laboratory of Stephen Briddon
(University of Nottingham)
Rose et al., 2012
Oligonucleotides
Oligonucleotides for sgRNA construction, see Table S1 Sigma Aldrich Custom Synthesis
Oligonucleotides for PCR amplification, see Table S1 Sigma Aldrich Custom Synthesis
Oligonucleotides for site directed mutagenesis, see
Method Details - Molecular Biology
Sigma Aldrich Custom Synthesis
Single stranded oligonucleotide for ADRB2 homology
directed repair template, see Table S2
Integrated DNA Technologies Custom Synthesis
Recombinant DNA
b-arrestin2-SmBiT This manuscript Custom synthesis
b-arrestin2-Halotag Tiulpakov et al., 2016 Custom synthesis
(Continued on next page)
Cell Chemical Biology 27, 1–12.e1–e7, April 16, 2020 e1
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
cDNA encoding NSGSSGGGGSGGGGSSG-LgBiT for
sub-cloning
GeneArt (Thermo Fisher
Scientific)
Custom synthesis
CXCR4-LgBiT This manuscript Custom synthesis
HiBiT-ACKR3 This manuscript Custom synthesis
HiBiT-CXCR4 This manuscript Custom synthesis
Homology directed repair templates, see Table S2 GeneArt (Thermo Fisher Scientific) Custom synthesis
NanoLuc-ACRK3 This manuscript Custom synthesis
NanoLuc-CXCR4 This manuscript Custom synthesis
pSpCas9(BB)-2A-Puro (PX459) V2.0 Addgene Plasmid Cat # 62988;
RRID: Addgene_62988
Software and Algorithms
GraphPad Prism 7.02 GraphPad Software, La Jolla
California USA
https://www.graphpad.com/
scientific-software/prism/
Other
35 mm dish containing a high tolerance
1.5 mm coverslip
MatTek Cat# P35G-0.170-14-C
BamHI-HF Restriction enzyme New England Biolabs (UK) Cat# R3136
Kpn-HF Restriction enzyme New England Biolabs (UK) Cat# R3142
PHERAStar FS plate reader BMGLabTech PHERAStar FS plate reader
Olympus LV200 wide field inverted microscope Olympus Olympus LV200 wide field inverted
microscope
Q5 High-Fidelity DNA Polymerase New England Biolabs (UK) Cat# M0491
XbaI Restriction enzyme New England Biolabs (UK) Cat# R0145
XhoI Restriction enzyme New England Biolabs (UK) Cat# R0146
White 96-well plates Greiner Bio-One Cat# 655089
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact,
Stephen J Hill (stephen.hill@nottingham.ac.uk). All unique/stable reagents generated in this study are available from the Lead Con-
tact without restriction.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human HEK293FT cells (female) were obtained from (Life Technologies). Human HeLa cells (female) were obtained from Dr. Stephen
Briddon (University of Nottingham) (Rose et al., 2012). Cells lines were not subsequently authenticated. HeLa and HEK293T cells
were transfected and cultured as described in Method Details.
METHOD DETAILS
Materials
AMD3100 was purchased from Selleckchem (USA), CXCL11 and CXCL12 were purchased from Preprotech (USA). CXCL12-AF647
was purchased from Almac (United Kingdom). N,N’-Dicyclohexylcarbamimidothioic acid (5,6-dihydro-6,6-dimethylimidazo[2,1-b]
thiazol-3-yl)methyl ester dihydrochloride (IT1t) was purchased from Tocris (United Kingdom)., isoprenaline hydrochloride, (±)-pro-
pranolol hydrochloride, saponin, and xanthine amine congener (XAC) were from Sigma-Aldrich, (United Kingdom). Furimazine, pu-
rified HiBiT (HiBiT-Halotag, control peptide) and purified LgBiT NLuc fragments were purchased from Promega (USA), affinities and
modifications of the fragments from the native NLuc protein have been described previously by the manufacturer (Dixon et al., 2016).
Purified full length NLuc was a kind gift from Matt Robers (Promega, USA). AM3100, isporenaline, and propranolol were dissolved in
water, CXCL11, CXCL12 and CXCL12-AF647 were dissolved as per the manufacturer’s instructions. Isoprenaline, IT1t (10 mM), pro-
pranolol (10 mM) and XAC (10 mM) were dissolved in DMSO. All further dilutions were performed in assay buffer containing 0.1%
bovine serum albumin (BSA, Sigma-Aldrich, United Kingdom).e2 Cell Chemical Biology 27, 1–12.e1–e7, April 16, 2020
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The CXCR4 and ACKR3 cDNA sequences were provided through the ONCORNET consortium from Vrije Universiteit Amsterdam in
pcDEF3 plasmids. To generate pCDNA3.1 (+) neo expression constructs encoding NLuc/CXCR4 an internal BamHI restriction site
was first removed by site directed mutagenesis. The primers used were forward 5’-GGCGTCTGGATTCCTGCCCTCCTGC-3’ and
reverse 5’- GCAGGAGGGCAGGAATCCAGACGCC -3’. The mutated CXCR4 sequence was then PCR amplified to generate a
CXCR4 sequence that was in frame with the BamHI restriction site of sig-NLuc (Stoddart et al., 2015), and changed the start codon
(Met) of the CXCR4 sequence to (Leu). The primers used were forward 5’-CCCGGATCCCTGGAGGGGATCAGTATATAC-3’ and
reverse 5’-GGGCTCGAGTTAGCTGGAGTGAAAACTTG-3’. To generate pCDNA3.1 (+) neo expression constructs encoding NLuc/
ACKR3, ACKR3 was PCR amplified to generate an ACKR3 sequence that was in frame with the BamHI restriction site of sig-
NLuc, and changed the start codon (Met) of the ACKR3 sequence to (Leu). The primers used were forward 5’-CCCGGATCCCTG
GATCTGCATCTCTTCG-3’ and reverse 5’-GGGCTCGAGTCATTTGGTGCTCTGCTCC-3’. Additional deoxyadenosines were added
to both ACKR3 and CXCR4 PCR products by incubation Taq polymerase and then ligated into a pcDNA2.1 vector by standard TA
cloning. The ACKR3 and mutated CXCR4 sequences were then ligated inframe from the pcDNA2.1 vector into pcDNA3.1 (+) neo
vectors containing sig-NLuc using the restriction enzymes BamHI and XhoI. pCDNA3.1 (+) neo constructs encoding HiBiT/
CXCR4 or HiBiT/ACKR3 were generated by ligation of HiBiT-GSSG into NLuc/CXCR4 or NLuc/ACKR3 plasmid constructs digested
with KpnI and BamHI using the complementary oligonucleotides 5’-CATGGTGAGCGGCTGGCGGCTGTTCAAGAAGATTAGC
GGGAGTTCTGGCGGCTCGAGCGGTG-3’ and 5’-GATCCACCGCTCGAGCCGCCAGAACTCCCGCTAATCTTCTTGAACAGCCGC
CAGCCGCTCACCATGGTAC -3’. To generate the CXCR4/LgBiT pcDNA3.1 expression construct, NSGSSGGGGSGGGGSSG-
LgBiT synthesised by GeneArt was sub-cloned into pcDNA3.1 CXCR4 (White et al., 2017) using the restriction enzymes XhoI and
XbaI. The cDNA expression construct encoding b-arrestin2/Halotag has been described previously (Tiulpakov et al., 2016). To
generate the cDNA expression construct encoding b-arrestin2/NSGSSGGGGSGGGGSSG-SmBiT, cDNA sequences encoding
linker-SmBiT where provided by Promega in a pNBe2 vector. An internal XhoI restriction site was first removed by site directedmuta-
genesis. The primers used were forward 5’- CGCCACCACCGCTGGAGCCAGAATTCC -3’ and reverse 5’- GGAATTCTGGCTCC
AGCGGTGGTGGCG -3’. An in frame XhoI restriction site was then inserted by site directed mutagenesis. The primers used were
forward 5’- CTCGAGCCAGAATTCTCGAGAGCTCCCACGGCGA -3’ and reverse 5’- TCGCCGTGGGAGCTCTCGAGAATTCTG
GCTCGAG -3’. The resulting NSGSSGGGGSGGGGSSG-SmBiT fragment was then sub-cloned in frame into a pcDNA3.1 expression
construct encoding b-arrestin2 described previously (Tiulpakov et al., 2016) using the restrictions enzymes XhoI and XbaI.
CRISPR/Cas9 Genome Engineering
Guide RNA construction was performed as described previously in the detailed protocol (Ran et al., 2013). Briefly, guide sequences
were designed using the CRISPR Design Tool (http://crispr.mit.edu/) and ligated as complementary oligonucleotides (Table S1) into
the pSpCas9(BB)-2A-Puro (PX459 V2) expression construct (from Feng Zhang, Addgene plasmid # 62988) linearized by
the restriction enzyme BbsI (NEB). Guide sequences used to target Cas9 to the genomic loci were; for CXCR4 N-terminus; guide-
RNA1, ATCCCCTCCATGGTAACCGC, and guideRNA2, TGGAGAACCAGCGGTTACCA, for ACKR3 N-terminus; guideRNA1,
GATTGCCCGCCTCAGAACGA and guideRNA2, GATGCAGATCCATCGTTCTG, to knockout CXCL12 by InDel formation Cas9
was targeted to the N-terminal region using guideRNA1, GGCATGGGCATCTGTAGCTC and guideRNA2, CATCTGTAGCTCAGGCT
GAC. The guide RNA sequences used to target the CXCR4 and ARRB2 C-terminus have been described previously (White et al.,
2017), as have the guide RNA sequences used to target the N-terminus of ADRB2 (Kilpatrick et al., 2019).
To introduce DNA encoding NLuc or NanoBiT fragments donor repair templates (Table S2) were designed using the UCSCgenome
browser (http://genome.ucsc.edu/), Human genome assembly (GRCh38/hg38). Briefly, for N-terminal tagging of CXCR4 with NLuc
(NLuc/CXCR4) a donor template consisting of left homology arm - sig-NLuc – right homology arm surrounding but not including the
genomic start codonwere synthesized as double stranded DNA in pMX cloning vectors byGeneArt (Invitrogen). To introduce HiBiT to
the N-terminus of CXCR4 (HiBiT/CXCR4), an internal KpnI restriction site in the repair template was silently mutated, using the
primers 5’-CCAGGACATTGGAGGTGCCCGTACTCCAAAAAAG-3’ and 5’-CTTTTTTGGAGTACGGGCACCTCCAATGTCCTGG-3’,
a KpnI restriction site was then introduced at the end of the left homology arm using the primers 5’-GAGAACCAGCGGGTACCAT
GAGGTTG-3’ and 5’-CAACCTCATGGTACCCGCTGGTTCTC-3’ to allow ligation of HiBiT-GSSG into the template using the restric-
tion enzymes KpnI and BamHI and the complementary oligonucleotides 5’-CATGGTGAGCGGCTGGCGGCTGTTCAAGAAGATT
AGCGGGAGTTCTGGCGGCTCGAGCGGTG-3’ and 5’-GATCCACCGCTCGAGCCGCCAGAACTCCCGCTAATCTTCTTGAACAGCC
GCCAGCCGCTCACCATGGTAC -3’. For N-terminal tagging of ACRK3 (NLuc/ACKR3) a donor template consisting of areas of homol-
ogy surrounding but not including the ACKR3 start codon were synthesized as double stranded DNA by GeneArt (Invitrogen) a short
linker was included between the homology arms to allow ligation of sig-NLuc into the template using the restriction enzymes KpnI and
BamHI. The donor templates for N-terminus tagging therefore resulted in cells expressing genome-edited sig-Nluc or HiBiT-GSSG
receptor with the start codon (Met) of the receptor deleted. For tagging the N-terminus of ADRB2 with HiBiT, a repair template was
synthesised as a single stranded oligo DNA nucleotide (ssODN; Integrated DNA Technologies; IDT) and consisted of homology arms
surrounding HiBiT-GSSG with the start codon (Met) of ADRB2 deleted. To insert SmBiT into the ARRB2 genomic loci (b-arrestin2/
SmBiT) a donor template consisting of homology arms surrounding but not including the ARRB2 stop codon was synthesized as
double stranded DNA by GeneArt (Invitrogen). A short linker was included between the homology arms to allow ligation of
GGGGSGGGGGSSG-SmBiT into the template using the restriction enzymes XhoI and XbaI and the complementary oligonucleotides
5’- TCGAGGGTGGTGGCGGGAGCGGAGGTGGAGGGTCGTCAGGTGTGACCGGCTACCGGCTGTTCGAGGAGATTCTGTAAT-3’Cell Chemical Biology 27, 1–12.e1–e7, April 16, 2020 e3
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To tag CXCR4 on the C-terminus with LgBiT (CXCR4/LgBiT), NSGSSGGGGSGGGGSSG-LgBiT was sub-cloned from the pcDNA3.1
CXCR4/LgBiT construct into the CXCR4 C-terminal repair template (White et al., 2017) using the restriction enzymes XhoI and XbaI.
Cell Culture
HEK293T or HeLa cells were maintained in Dulbecco’s Modified Eagle’s Medium (Sigma Aldrich) supplemented with 10 % fetal calf
serum at 37C/5%CO2. Transfections were performed using FuGENE (Promega, USA) according to themanufacturer’s instructions.
Cell were passaged or harvested when cells reached 70-80% confluency using Phosphate Buffered Saline (PBS, Sigma Aldrich) and
trypsin (0.25% w/v in versene; Sigma Aldrich). To generate cells stably expressing tagged receptors, cells were transfected with a
pcDNA3.1 (+) neo expression vector encoding NLuc/CXCR4, HiBiT/CXCR4, NLuc/ACKR3 or HiBiT/ACKR3 and subsequently
selected for incorporation of the transgene usingG418 (ThermoFisher). CRISPR/Cas9 genome-engineering of HEK293 cells was per-
formed as described previously (White et al., 2017; Ran et al., 2013). Briefly, HEK293 or HeLa cells were seeded in 6 well plates at
300,000 cells per well and incubated for 24h at 37C/5%CO2. Cells were then transfected with px459 sgRNA/Cas9 expression con-
structs and either plasmid or ssODN encoding for the donor repair template. Cells were cultured for 24h then treated with puromycin
(0.3 mg/ml, Sigma-Aldrich) for 3 days to select for transfected cells. Following selection, cells were cultured without puromyocin for
1 day then seeded into clear flat bottom 96-well plates at 1 cell per well and allowed to expand for 2-3 weeks. To knockout CXCL12,
HEK293 cells were transfected with px459 sgRNA/Cas9 expression constructs targeting the first exon of CXCL12 and selected and
cloned as per the method used for tagging. To create cells expressing both b-arrestin2/SmBiT and CXCR4/LgBiT, cells expressing
b-arrestin2/SmBiT were first generated then CXCR4 was tagged with LgBiT in a subsequent round of transfection and clonal
isolation.
Screening of Genome-Edited Clones
Following clonal expansion single colonies expressing NLuc/CXCR4, NLuc/ACKR3 or CXCR4/LgBiT and b-arrestin2/SmBiT were
screened for luminescence following the addition of furimazine (10 mM) using a PHERAStar FS plate reader. Clones expressing
HiBiT/CXCR4 or HiBiT/b2-adrenoceptor were screened by addition of furimazine (10 mM) and purified LgBiT (10 nM). Cells expressing
CXCR4/LgBiT were lysed and screened for luminescence following the addition of furimazine (10 mM) and purified HiBiT (10 nM,
Promega). To screen for clones expressing b-arrestin2/SmBiT following expansion, cells were harvested and seeded into poly-D-
lysine coated white flat bottom 96well plates and transiently transfected with a pcDNA3.1 expression vector encoding CXCR4/LgBiT
(0.025 mg/well) using FuGENE and incubated for 24h. On the day of screening, cells were washed and incubated with pre-warmed 1x
HEPES Buffered Salt Solution (1xHBSS; 25mM HEPES, 10mM glucose, 146mM NaCl, 5mM KCl, 1mM MgSO4, 2mM sodium pyru-
vate, 1.3mM CaCl2, 1.8g/L glucose; pH 7.2), for 1h. Cells were then incubated with furimazine (10 mM) for 5 minutes at 37
C before
total light emissions were measured on a PHERAStar FS plate reader before and after the addition of CXCL12 (100 nM). Positive
clones displayed an increase in luminescence following ligand addition. Positive clones were collected for genotyping and/or
mRNA quantification by RTqPCR. Genotyping was performed by PCR amplification of genomic DNA using Q5 High-Fidelity
DNAPolymerase (NewEngland BioLabs) as per themanufacturer’s instructions and primer sets described in Table S1. Heterozygous
insertion of tags into the genomic loci was observed for all cell lines tested.
RTqPCR
Total RNA from wildtype or genome-edited cells was extracted using a ReliaPrep RNA extraction kit (Promega) as per the manu-
facturer’s instructions followed by cDNA synthesis using the Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific)
following manufacturer’s instructions. qPCR was performed on QuantStudio 7 (Applied Biosystems) using PowerUp SYBR Green
Master Mix (Thermo Fisher Scientific) and primers listed in Table S1. RTqPCR primers designed in-house except for Human
ARRB2 primers which were described previously (Yang et al., 2015). Target gene expression was normalised to B2M expression,
amplified using Hs_B2M_1_SQ QuantiTect Primer Assay (QT00088935; Qiagen).
Widefield Bioluminescence Microscopy
Bioluminescence imaging was performed using an Olympus LV200 wide field inverted microscope, equipped with a 60x/1.42NA oil
immersion objective lens and 0.5x tube lens. 24h before imaging cells were seeded into a 35 mm dish containing a high tolerance
1.5 mm coverslip (MatTek). On the day of imaging, medium was removed and cells were incubated with 2 mL HBSS for 30 minutes
at 37o C before furimazine (400 nM) was added and allowed to equilibrate for 5minutes at 37oC. Luminescence images were taken by
capturing total luminescence for (90 sec exposure time). HiBiT/CXCR4 cells were incubated with furimazine (400 nM) and purified
LgBiT (10 nM) for 5 minutes at 37oC prior to imaging.
Membrane Preparation
Membrane preparations were made as described previously (Bouzo-Lorenzo et al., 2019). Briefly, cells expressing NLuc or HiBiT
tagged receptors were grown to 80-90% confluence in 500 cm2 dishes or T175 flasks. Cells were washed with PBS and collected
using a cell scraper or by pre-warmed non-enzymatic dissociation solution (PBS containing 0.2 g/L EDTA), cells were then pelleted,
resuspended in ice-cold PBS and homogenised. Unbroken cells and nuclear fraction were removed by centrifugation at 1200 x ɡ for
10 minutes at 4C before the supernatant was centrifuged at 40,000 x ɡ for 30 minute at 4C to obtain the membrane fraction. Thee4 Cell Chemical Biology 27, 1–12.e1–e7, April 16, 2020
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Quantification of Tagged Protein by Luciferase Activity
Quantification of NLuc-tagged receptors expressed in genome-edited cells was determined by interpolation against a purified NLuc
standard curve, (R2 = 0.994 ± 0.0017, Slope = 0.94 ± 0.016, slopes not different from unity p>0.05, mean ± s.e.m). On the day of
assay, membrane preparations made from genome-edited HEK293 or HeLa cells were diluted to 1 mg/well in HBSS supplemented
with 0.1% BSA and loaded into a white flat bottom 96 well plate in triplicate. A log NLuc standard curve (10 fmol - 100 nM) was con-
structed in parallel by diluting purified NLuc in HBSS supplemented with 0.1%BSA and adding to wells containing 1 mg/well wildtype
HEK293 membranes. Plates were incubated for 10 minutes at 37C before 10 mM furimazine was added. Total light emissions were
measured on a PHERAStar FS plate reader after a further 5 minutes incubation.
NanoBRET Saturation Ligand Binding Assays
Genome-edited or cells stably expressing NLuc/CXCR4 or NLuc/ACKR3 were seeded into poly-D-lysine coated white flat bottom 96
well plates at 30,000 cells/well and incubated for 24h at 37C/5%CO2. On the day of the assay, cells were washed and incubatedwith
pre-warmed HBSS supplemented with 0.1% BSA. For assays using membrane preparations, 10 mg membrane protein diluted in
HBSS 0.1% BSA was loaded into each well on the day of assay. Cells or membranes were then incubated with increasing concen-
trations of CXCL12-AF647 in the absence or presence of AMD3100 (10 mM) or CXCL11 (10 mM) for NLuc or HiBiT/CXCR4 and NLuc/
ACKR3 respectively for 60 minutes at 37C. Following ligand incubation, 10 mM of the NLuc substrate furimazine was added and
plates equilibrated for 5 minutes at room temperature. For cells expressing HiBiT/CXCR4 following ligand incubation both furimazine
(10 mM) and purified LgBiT (10 nM) were added. Sequential filtered light emissions were taken using a PHERAStar FS plate reader
using 460nm (80nm bandpass) and >610nm (longpass) filters. BRET ratios were calculated by dividing the 610nm emission
(acceptor) by the 460nm emission (donor).
NanoBRET Competition Ligand Binding Assays in Non-clonal Cells
HEK293 cells were seeded in 6 well plates at 300,000 cells per well and incubated for 24h at 37C/5% CO2, cells were then trans-
fected with px459 sgRNA/Cas9 expression constructs and plasmid encoding the NLuc/CXCR4 donor repair template or for the
negative control, plasmid encoding the NLuc/CXCR4 donor repair template only and untargeted px459 sgRNA/Cas9 expression
constructs. Cells were cultured for 24h then treated with puromycin (0.3 mg/mL) for 2 days to select for transfected cells. Cells
were then allowed to recover and expand for three days. Cells were then seeded into poly-D-lysine coated white flat bottom 96
well plates at 30,000 cells/well and incubated for 24h at 37C/5% CO2. On the day of the assay, cells were washed and incubated
with pre-warmed HBSS supplemented with 0.1% BSA. Cells were incubated with CXCL12-AF647 (12.5 nM) in the absence or pres-
ence of AMD3100 (10 pM – 10 mM) for 60 minutes at 37C. Following ligand incubation, 10 mM of the NLuc substrate furimazine was
added and plates equilibrated for 5 minutes at room temperature. Sequential filtered light emissions were taken using a PHERAStar
FS plate reader using 460nm (80nm bandpass) and >610nm (longpass) filters. BRET ratios were calculated by dividing the 610nm
emission (acceptor) by the 460nm emission (donor).
b-arrestin2 Recruitment Assays
Wildtype HEK293 cells or HEK293 cells expressing genome-edited b-arrestin2/SmBiT or genome-edited CXCR4/LgBiT were seeded
in 6 well plates at 300,000 cells per well and incubated for 24h at 37C/5% CO2. Wildtype HEK293 cells were then transfected with
plasmid DNA encoding CXCR4/LgBiT and b-arrestin2/SmBiT (25 ng of each per well of a 6 well plate). For HEK293 cells expressing
genome-edited b-arrestin2/SmBiT or CXCR4/LgBiT, cells were transfected with CXCR4/LgBiT only or b-arrestin2/SmBiT only
respectively (25 ng of plasmid DNA per well of a 6 well plate). 25ng plasmid DNA was chosen to approximate the levels of CXCR4
and b-arrestin2 expression we observed previously in genome-edited HEK293 cells (White et al., 2017). Cells were then incubated
for 24h at 37C/5%CO2 before being seeded into poly-D-lysine coated white flat bottom 96well plates, at 30,000 cells/well and incu-
bated for a further 24h. HEK293 cells expressing both genome-edited CXCR4/LgBiT and b-arrestin2/SmBiT cells were seeded at
100,000 cells/well. On the day of assay, cells were washed and incubated with pre-warmed HBSS containing 0.1% BSA for 30 mi-
nutes at 37C. Cells were pre-incubated with or without AMD3100 (1 mM) for 30minutes at 37Cbefore furimazine (10 mM)was added
to cells and allowed to equilibrate for 5minutes. Total luminescence wasmeasured on a PHERAStar FS plate reader, with basal mea-
surements taken before HBSS or half log increasing concentrations of CXCL12 (0.3 nM - 300 nM) were added at time = 0 and total
luminescence was measured. In a subset of experiments HEK293 cells expressing genome-edited b-arrestin2/SmBiT or both
genome-edited CXCR4/LgBiT and b-arrestin2/SmBiT were additionally transiently transfected with 500 ng per well of a 6 well plate
with b-arrestin2/Halotag (unlabelled) and cells were seeded as above. On the day of assay, cells were prepared as above and HBSS
or CXCL12 (300 nM) was added at time = zero. Baseline-corrected luminescence was calculated by subtracting the vehicle-treated
and/or mean basal luminescence from the ligand-treated luminescence. Basal luminescence for each configuration was calculated
from the luminescence measurement immediately before the addition of ligand.Cell Chemical Biology 27, 1–12.e1–e7, April 16, 2020 e5
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For end point internalisation/cell surface expression assays, genome-edited or HEK293 cells stably expressing HiBiT/CXCR4, HiBiT/
ACKR3 or HiBiT/b2-adrenoceptors were seeded into poly-D-lysine coated white flat bottom 96 well plates at 30,000 cells/well and
incubated for 24h at 37C/5%CO2. On the day of the assay, cells were washed and incubatedwith pre-warmedHBSS supplemented
with 0.1% BSA. To generate log concentration response curves, cells expressing HiBiT/CXCR4 were incubated in the absence or
presence of CXCL12, AMD3100, IT1t or XAC. HEK293 cells expressing exogenous HiBiT/ACKR3 were incubated in the absence
or presence of CXCL12 or CXCL11 and HEK293 cells expressing HiBiT/b2-adrenceptors were incubated in the absence or presence
of isoprenaline or propranolol for 60 minutes at 37C. To generate CXCL12 concentration response curves in the presence of
AMD3100 in membrane preparations, 10 mg membrane protein diluted in HBSS supplemented with 0.1% BSA was loaded into
each well containing 0.25 mg/mL saponin. Membranes were then incubated with AMD3100 (1 mM) in the absence or presence of
CXCL12 for 60 minutes at 37C. Following ligand incubation, furimazine (10 mM) and purified LgBiT (10 nM) were added, plates
were incubated for 5 minutes and total light emissions were measured using a PHERAStar FS plate reader with the concentration
response curves representing the luminescence after 30 minutes.
For kinetic analysis of ligand induced changes in luminescence/cell surface expression, genome-edited or HEK293 cells stably
expressing HiBiT/CXCR4 were seeded into poly-D-lysine coated white flat bottom 96 well plates at 30,000 cells/well and incubated
for 24h at 37C/5% CO2. On the day of assay, cells were washed and incubated with pre-warmed HBSS supplemented with 0.1%
BSA. For assays using membrane preparations, 10 mgmembrane protein diluted in HBSS supplemented with 0.1%BSAwas loaded
into each well containing 0.25 mg/mL saponin. 10 nM purified LgBiT was then added to each well and cells incubated for 60 minutes
at 37C. Following ligand incubation, furimazine (10 mM) was added, plates incubated for 5 minutes and total light emissions were
measured using a PHERAStar FS plate reader at 37C for 5 reads before CXCL12, AMD3100, IT1t or XAC were added to cells
and measurement of total light emissions was continued. The concentration response curves with membrane preparations were
generated in this manner with points representing the luminescence at 30minutes. Baseline-corrected luminescence was calculated
by subtracting vehicle-treated luminescence from the ligand-treated luminescence and/or by subtracting the mean of the pre-ligand
addition basal reads from the ligand-treated luminescence.
Determination of NanoBiT Affinity
To investigate the affinity of HiBiT-LgBiT complementation, HEK293 cells expressing genome-edited HiBiT/CXCR4 or HiBiT/b2-adre-
noceptors as well wildtype HEK293 cells were seeded into poly-D-lysine coated white flat bottom 96 well plates at 30,000 cells/well
and incubated for 24h at 37C/5% CO2. On the day of the assay, cells were washed and incubated with HBSS supplemented with
0.1% BSA 60 minutes at 37C. Cells were then incubated with increasing concentrations of purified LgBiT for 30 minutes at 37C.
Following LgBiT incubation, furimazine (10 mM) was added, plates incubated for 5 minutes and total light emissions were measured
using a PHERAStar FS plate reader. For assays using membrane preparations 10 mg membrane protein from genome-edited HiBiT/
CXCR4 cells diluted in HBSS supplemented with 0.1% BSA was loaded into each well containing 0.25 mg/ml saponin. For assays
using both purified HiBiT and LgBiT, 1 nM purified HiBiT-control protein (HiBiT-Halotag) diluted in HBSS supplemented with 0.1%
BSA was loaded into each well. To determine the effect of AMD3100, samples were then incubated in the absence or presence
of AMD3100 (10 mM) for 30 minutes at 37C. In parallel non-specific luminescence/binding was determined by adding purified LgBiT
to wells containing wildtype cells or membranes, or for HiBiT-control protein HBSS containing 0.1% BSA. Following incubation, fur-
imazine (10 mM) was added, plates incubated for 5 minutes and total light emissions measured using a PHERAStar FS plate reader.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data Presentation and Statistical Analysis
Due to differences in NLuc expression between cell lines, optimised plate reader filtered light emission gains were used to ensure
sufficient sensitivity and/or measurements acquired did not saturate the detector. Therefore, raw BRET ratios and luminescence
values cannot be compared as a measure of BRET efficacy or expression between cells lines or assay conditions. However, gains
used to acquire total luminescence for NanoBiT b-arrestin2 recruitment were consistent between assays. In general, BRET ratios
were calculated by dividing the acceptor emission by the donor emission. Calculation of baseline-corrected BRET ratios or lumines-
cence values are described in the methods for each assay configuration.
Prism 7 software was used to analyse ligand-binding curves. For NanoBRET receptor-ligand saturation binding assays total and
non-specific saturation binding curves were simultaneously fitted using the following equation:
BRET Ratio=
Bmax  ½B
½B+Kd + ððM  ½B Þ+C Þ
where Bmax is themaximal response, [B] is the concentration of fluorescent ligand in nM, Kd is the equilibrium dissociation constant in
nM, M is the slope of the non-specific binding component and C is the intercept with the Y-axis. For HiBiT-LgBiT, complementation
affinity was determined as per the NanoBRET saturation binding but with luminescence generated by LgBiT, [B] incubated on wild-
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Response=
Emax  ½A
EC50 + ½A
Where Emax is themaximum response, EC50 is the concentration of agonist required to produce 50%of themaximal response and [A]
is the agonist concentration. pEC50 calculated at approximately 5 minutes post ligand addition.
Inhibition concentration-response data were fitted using the following equation:
Inhibition=
Emax  ½A
IC50 + ½A
where [A] is the concentration of competing ligand, Emax is themaximum specific binding or responsemediated by a probe and IC50 is
the molar concentration of this competing ligand required to inhibit 50% of the specific response or binding. pKd, pIC50 and pEC50
values were calculated as –log Kd, –log IC50 and –log EC50 respectively.
Quantification of NLuc or HiBiT tagged protein expression was interpolated by Prism from linear regression of a log-log standard
curve fitted with the following equation:
Y = A+B½X
where [X] is the concentration of NanoLuc or HiBiT, Y is the luminescence output, A is the y-intercept and B is the slope of the line.
Statistical analysis was performed using Prism 7 software (GraphPad, San Diego, USA) using one or two-way ANOVA with an
appropriate multiple comparisons tests where required. Specific statistical tests used are indicated in the figure legends and
were performed on the mean data of individual experiments (n) also indicated in the figure legends. A p-value <0.05 was considered
statistically significant.
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